...
首页> 外文期刊>Stem cells international >Mesenchymal Stem Cell Therapy Facilitates Donor Lung Preservation by Reducing Oxidative Damage during Ischemia
【24h】

Mesenchymal Stem Cell Therapy Facilitates Donor Lung Preservation by Reducing Oxidative Damage during Ischemia

机译:间充质干细胞疗法通过降低缺血期间的氧化损伤来促进供体肺保存

获取原文

摘要

Lung transplantation is a lifesaving therapy for people living with severe, life-threatening lung disease. The high mortality rate among patients awaiting transplantation is mainly due to the low percentage of lungs that are deemed acceptable for implantation. Thus, the current shortage of lung donors may be significantly reduced by implementing different therapeutic strategies which facilitate both organ preservation and recovery. Here, we studied whether the anti-inflammatory effect of human umbilical cord-derived mesenchymal stem cells (HUCPVCs) increases lung availability by improving organ preservation. We developed a lung preservation rat model that mimics the different stages by which donor organs must undergo before implantation. The therapeutic schema was as follows: cardiac arrest, warm ischemia (2?h at room temperature), cold ischemia (1.5?h at 4°C, with Perfadex), and normothermic lung perfusion with ventilation (Steen solution, 1?h). After 1?h of warm ischemia, HUCPVCs (1×106 cells) or vehicle was infused via the pulmonary artery. Physiologic data (pressure-volume curves) were acquired right after the cardiac arrest and at the end of the perfusion. Interestingly, although lung edema did not change among groups, lung compliance dropped to 34% in the HUCPVC-treated group, while the vehicle group showed a stronger reduction (69%, p0.0001). Histologic assessment demonstrated less overall inflammation in the HUCPVC-treated lungs. In addition, MPO activity, a neutrophil marker, was reduced by 41% compared with vehicle (p0.01). MSC therapy significantly decreased tissue oxidative damage by controlling reactive oxygen species production. Accordingly, catalase and superoxide dismutase enzyme activities remained at baseline levels. In conclusion, these results demonstrate that the anti-inflammatory effect of MSCs protects donor lungs against ischemic injury and postulates MSC therapy as a novel tool for organ preservation.
机译:肺移植是患有严重危及生命肺病的人的救生疗法。等待移植的患者的高死亡率主要是由于植入可接受的肺部百分比低。因此,通过实施不同的治疗策略,可以显着降低目前的肺部供体短缺,这促进了器官保存和恢复。在这里,我们研究了人脐带的间充质干细胞(HUCPVCs)的抗炎作用是否通过改善器官保存来增加肺可用性。我们开发了一种肺保存大鼠模型,模拟供体器官必须在植入前进行的不同阶段。治疗方法如下:心脏骤停,温暖的缺血(室温下2℃),冷缺血(1.5℃,4°C,具有Perfadex),以及通风的常温肺灌注(Steen溶液,1Ωh) 。在温热缺血1℃后,通过肺动脉注入HUCPVCs(1×106个细胞)或载体。在心脏骤停后和灌注结束后获得生理数据(压力体积曲线)。有趣的是,虽然肺水肿在群体中没有改变,但肺血症治疗组中的肺顺应性降至34%,而载体组均显示出更强的减少(69%,P <0.0001)。组织学评估在HUCPVC治疗的肺中表现出较少的整体炎症。此外,与载体相比,MPO活性,中性粒细胞标记物减少了41%(P <0.01)。通过控制反应性氧物种生产,MSC治疗显着降低了组织氧化损伤。因此,过氧化氢酶和超氧化物歧化酶酶活性仍处于基线水平。总之,这些结果表明,MSCs的抗炎作用保护供体肺抗缺血性损伤,并将MSC疗法假定为器官保存的新型工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号